Company profile: Artelo Biosciences
1.1 - Company Overview
Company description
- Provider of endocannabinoid system modulating therapeutics, including ART27.13, a synthetic dual CB1/CB2 GPCR agonist intended to increase appetite and reduce muscle wasting; ART26.12, a selective fatty acid binding protein inhibitor with potential in cancer and chemotherapy-induced peripheral neuropathy; and ART12.11, a proprietary cannabidiol–tetramethylpyrazine cocrystal designed to improve CBD's pharmaceutical properties.
Products and services
- ART12.11: A proprietary cocrystal of cannabidiol and tetramethylpyrazine designed to improve CBD’s pharmaceutical properties for endocannabinoid system modulating therapeutics
- ART26.12: A selective inhibitor targeting Fatty Acid Binding Proteins with potential applications in cancer treatment and managing Chemotherapy-Induced Peripheral Neuropathy within endocannabinoid system therapeutics
- ART27.13: A synthetic dual G-protein-coupled receptor agonist targeting CB1 and CB2 receptors intended to increase appetite and reduce muscle wasting for endocannabinoid system modulating therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Artelo Biosciences
Zymenex
HQ: Denmark
Website
- Description: Provider of novel enzyme replacement therapies for life-threatening, rare genetic diseases; a Scandinavian biopharmaceutical company developing and commercializing human recombinant enzymes for therapeutic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zymenex company profile →
Spruce Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for rare endocrine diseases, including tildacerfont, a CRF1 receptor antagonist in late-stage clinical trials for classic congenital adrenal hyperplasia and potentially other conditions with elevated ACTH. Conducts CAHMELIA 203, a double-blind, placebo-controlled, dose-ranging study evaluating tildacerfont's efficacy and safety in adults with CAH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spruce Biosciences company profile →
Cogent Biosciences
HQ: United States
Website
- Description: Provider of therapies for solid cancer tumors as a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cogent Biosciences company profile →
Cydan
HQ: United States
Website
- Description: Provider of orphan drug accelerator services focused on identifying and de-risking compounds with therapeutic and commercial potential.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cydan company profile →
eTherapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development solutions using proprietary computational systems to analyze and predict medicine–cell interactions, optimizing efficacy and minimal side effects. Includes HepNet™ computational biology and GalOmic™ RNAi platforms, with candidates ETX-312 (MASH), ETX-407 (dAMD), ETX-148 (haemophilia), and ETX-291 (cardiometabolic).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Artelo Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Artelo Biosciences
2.2 - Growth funds investing in similar companies to Artelo Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Artelo Biosciences
4.2 - Public trading comparable groups for Artelo Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →